![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 289, Issue 2, 877-885, May 1999
Research Service,
 |
Abstract |
|---|
 Top
 Abstract
 Introduction
Materials and Methods
Results
Discussion
References
|
|---|
We characterized the effects of drugs on the uptake of
[3H]neurotransmitter by and the binding of
[125I](3
-(4-iodophenyl)tropane-2-carboxylic acid
methyl ester ([125I]RTI-55) to the recombinant human
dopamine (hDAT), serotonin (hSERT), or norepinephrine (hNET)
transporters stably expressed in human embryonic kidney 293 cells.
RTI-55 had similar affinity for the hDAT and hSERT and lower affinity
for hNET (Kd = 1.83, 0.98, and 12.1 nM,
respectively). Kinetic analysis of [125I]RTI-55 binding
indicated that the dissociation rate (k
1) was significantly lower for hSERT and the association rate
(k+1) was significantly lower for hNET
compared with the hDAT. The potency of drugs at blocking
[3H]neurotransmitter uptake was highly correlated with
potency at blocking radioligand binding for hDAT and hSERT. Substrates
were more potent at the inhibition of
[3H]neurotransmitter uptake than radioligand binding. The
potency of drugs was highly correlated between displacement of
[3H]nisoxetine (Kd = 6.0 nM)
and [125I]RTI-55 from the hNET, suggesting that these
radioligands recognize similar sites on the transporter protein. The
correlation observed between inhibitory potency for uptake and binding
of either ligand at the hNET was lower than correlations between uptake
and binding for hDAT and hSERT. The present results indicate that the
cocaine analog [125I]RTI-55 has unique binding properties
at each of the transporters and that the use of recombinant
transporters expressed by a single cell type can provide a powerful
screening tool for drugs interacting with biogenic amine transporters,
such as possible cocaine antagonists.
| |
Introduction |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
Sodium-
and chloride-sensitive biogenic amine transporters are the major
mechanism for terminating the neurotransmission of dopamine (DA),
norepinephrine (NE), and serotonin (5-HT) (reviewed in Amara and Kuhar,
1993
). Abused drugs, such as cocaine and amphetamine, as well as
therapeutic agents such as mazindol and imipramine, inhibit
neurotransmitter uptake by the transporters and cause an increase in
synaptic neurotransmitter concentrations. In animal models of drug
abuse, the binding of cocaine and other drugs to the DAT may play a
critical role in self-administration (Ritz et al., 1987). The blockade
of DAT may also be involved in the reinforcing properties and abuse
potential of drugs in humans (Kuhar et al., 1991; Rothman et al.,
1993); indeed, the magnitude of DAT occupancy by cocaine in humans, as
measured by positron emission tomography, is correlated with
self-reported highs (Volkow et al., 1997). In addition, some abused
substances such as amphetamine are transporter substrates and induce
the release of neurotransmitter. Studies with DAT knockout mice (Giros
et al., 1996) confirm that these substrates have two sites of action:
release of DA from vesicular stores and via the DAT. The DAT is
necessary for increased extracellular DA concentrations after
amphetamine administration (Jones et al., 1998). However, other binding
sites for cocaine, perhaps including the NET and SERT, play important
roles in the behavioral effects of this drug because DAT knockout mice
will develop cocaine-conditioned place preference, a model for
assessment of drug reward (Sora et al., 1998).
An elusive goal of drug abuse pharmacotherapy has been the development
of a therapeutic agent for cocaine abuse (Vocci et al., 1995). Many
possible strategies are being investigated, including the development
of functional antagonists such as 
-vinyl--aminobutyric acid
(Morgan and Dewey, 1998), the development of vaccines to cocaine (Fox,
1997), the enhancement of cocaine metabolism via administration of
enzymes (Gorelick, 1997), or slow-onset, long-acting, agonist-based
medications (Glowa et al., 1996). One possible method of screening for
a pharmacological cocaine antagonist would be to compare the potencies
of compounds for inhibition of DA uptake and cocaine analog binding
under similar or identical conditions (Rothman et al., 1993; Slusher et
al., 1997). A compound that has much greater potency at inhibition of
binding than uptake may be a potential "DA-sparing" cocaine
antagonist. To establish a screening system, we stably expressed the
DAT, NET, and SERT in human embryonic kidney (HEK) 293 cells and
characterized cocaine analog binding and neurotransmitter uptake. The
transfected, adherent HEK 293 cells continued to take up
[3H]neurotransmitter after detachment from
tissue culture plates and were therefore useful for assays involving
robotic pipetting and assay termination by filtration. An array of
drugs, both therapeutic and those with abuse potential, was used to
pharmacologically characterize the transporters as expressed in these
non-neuronal cells.
| |
Materials and Methods |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
[3H]DA,
[3H]5-HT, [3H]NE, and
[125I]RTI-55 were purchased from Du Pont-New
England Nuclear (Boston, MA). Tropolone, DA, pargyline, and most other
reagents were purchased from Sigma Chemical Co. (St. Louis, MO). The
cloning and characterization of the hDAT cDNA used in these experiments
(pcDNA1-hDAT) were described previously (Eshleman et al., 1994, 1995).
The hSERT cDNA was generously supplied by Dr. Randy Blakely
(Ramamoorthy et al., 1993), subcloned into pcDNA1, and transfected into
HEK 293 cells through electroporation. Dr. Blakely also supplied us
with HEK cells transfected with pcDNA3-hNET (HEK-hNET; Galli et al.,
1995). RTI-55 and CFT were gifts from Dr. Ivy Carroll.
[125I]RTI-55 Binding. HEK-hDAT and HEK-hSERT cells were incubated in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum, 5% calf bovine serum, 0.05 U penicillin/streptomycin, and puromycin (2 µg/ml). HEK-hNET cells were incubated in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 0.05 U penicillin/streptomycin, and geneticin (300 µg/ml). Cells were grown until confluent on 150-mm-diameter tissue culture dishes in a humidified 10% CO2 environment at 37°C. Medium was removed from plates, cells were washed with 10 ml of PBS, lysis buffer (10 ml, 2 mM HEPES, 1 mM EDTA) was added, and plates were placed on ice for 10 min. Cells were scraped from plates and centrifuged for 20 min at 30,000g. The pellet was resuspended in 6 to 24 ml of 0.32 M sucrose with a Polytron homogenizer at setting 7 for 5 s.
Assays contained an aliquot of membrane preparation (approximately 12-30 µg protein, depending on the cell line, which resulted in binding <10% of the total radioactivity), drug, and [125I]RTI-55 (40-80 pM final concentration) in a final volume of 250 µl. Krebs-HEPES assay buffer (25 mM HEPES, 122 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 2.5 mM CaCl2, 1 µM pargyline, 100 µM tropolone, 2 mg glucose/ml, 0.2 mg ascorbic acid/ml, pH 7.4) was used for all assays. Specific binding was defined as the difference in binding observed in the presence and absence of 5 µM mazindol (HEK-hDAT and -NET) or 5 µM imipramine (HEK-hSERT). Membranes were preincubated with drugs at room temperature for 10 min before the addition of [125I]RTI-55, unless indicated otherwise. The reaction was incubated for 90 min at room temperature in the dark and was terminated by filtration through Wallac Filtermat A filters using a 96-well Tomtec cell harvester. Scintillation fluid (50 µl) was added to each filtered spot, and radioactivity remaining on the filter was determined using a Wallac 1205 Betaplate or 1405 microBeta scintillation counter. Competition experiments were conducted with duplicate determinations for each point. Saturation binding experiments were conducted in triplicate by diluting the specific activity of [125I]RTI-55 with unlabelled ligand ranging in concentration from 0.036 to 16 nM. The dissociation experiments were performed at 25°C after incubation with 50 pM [125I]RTI-55 for 90 min. The dissociation of the receptor-ligand complex was initiated by the addition of mazindol (5 µM), imipramine (5 µM), or RTI-55 (1 µM), as indicated, and terminated at dissociation times ranging from 1 to 120 min. The T1/2 and the dissociation rate constant, k1, were determined by
nonlinear regression of dissociation data. In association experiments,
membranes were incubated with [125I]RTI-55
(19-400 pM) at 25°C for 1 to 90 min. For association experiments
using higher concentrations of [125I]RTI-55 (1, 3, 6, and 10 nM), the specific activity of the radioligand was reduced
by dilution with RTI-55. The kobs
value at each concentration of radioligand was determined by
nonlinear regression; the association rate constant,
k+1, was determined from the slope of
the linear regression of kobs versus
the concentration of radioligand (Limbird, 1996).
[3H]Nisoxetine Binding to HEK-hNET Membranes.
Cells were prepared as described above and resuspended in 0.32 M
sucrose. Assay conditions were a modification of Tejani-Butt et al.
(1990) and included membranes (30-50 µg protein),
[3H]nisoxetine (20 nM final concentration),
drugs, and buffer (50 mM Tris, 300 mM NaCl, pH 7.4 at 4°C) in a final
volume of 250 µl. Specific binding was defined as the difference in
binding observed in the absence and presence of mazindol (5 µM). The
assay was incubated for 2 h at 4°C and then terminated by
filtration as described above. Concentrations of
[3H]nisoxetine ranging from 0.1 to 10 nM were
used to determine the Kd value for
binding to HEK-hNET cell membranes.
Concentration-Response Curves for Inhibition of Substrate Uptake by HEK-hDAT, -hSERT, and -hNET. HEK-hDAT, -hSERT, and -hNET cells were grown on 150-mm-diameter tissue culture dishes as described. Medium was removed and plates were washed twice with Ca2+, Mg2+-free PBS. Fresh Ca2+, Mg2+-free PBS (2.5 ml) was then added to each plate and plates were placed in a 25°C water bath for 5 min. Cells were gently scraped from plates, and cell clusters were separated by trituration with a pipette for 5 to 10 aspirations and ejections.
Aliquots (50 µl) of the suspended cells were added to assay tubes containing drugs and Krebs-HEPES assay buffer in a final assay volume of 0.5 ml. Competition experiments were conducted with triplicate determinations for each point. After a 10-min preincubation in a 25°C water bath (unless indicated otherwise), [3H]neurotransmitter (20 nM final concentration; [3H]DA, [3H]5-HT, or [3H]NE; 56, 26.9, or 60 Ci/mmol, respectively) was added, and the assay was incubated for 10 min. The reaction was terminated by filtration through Wallac filtermat A filters, presoaked in 0.05% polyethylenimine, using a Tomtec cell harvester. Scintillation fluid was added to each filtered spot, and radioactivity remaining on the filters was determined as described above. Specific uptake was defined as the difference in uptake observed in the absence and presence of 5 µM mazindol (hDAT and hNET) or 5 µM imipramine (hSERT).Data Analysis.
Prism software (GraphPad Software, San Diego,
CA) was used to analyze all kinetic, saturation, and competition
binding data. IC50 values were converted to
Ki values using the Cheng-Prusoff equation (Cheng and Prusoff, 1973).
| |
Results |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
The association and dissociation rates of
[125I]RTI-55 binding were characterized for
each cell line. The T1/2 for dissociation was 26.5 ± 5.2, 42.5 ± 6.5, and 30.1 ± 3.9 min, and
the calculated k1 values were
0.029 ± 0.004, 0.016 ± 0.003, and 0.028 ± 0.004 min1 for HEK-hDAT, -hSERT, and -hNET,
respectively (Fig. 1). In all hDAT and
hSERT dissociation experiments and the great majority of hNET
experiments (12 of 14 experiments), a single dissociation rate best fit
the data and there was no significant improvement in fit with a
two-site model. For each transporter, dissociation rates were identical
regardless of whether unlabeled RTI-55 or mazindol (hDAT and hNET) or
imipramine (hSERT) was used as the competing ligand. The dissociation
rate for hSERT was significantly slower than that for hDAT or hNET
(one-way ANOVA followed by a Tukey post-hoc analysis). The association
data indicated that equilibrium was approached by 60 min with hDAT and
hSERT and by 90 min with hNET at 20 and 50 pM
[125I]RTI-55, the lowest concentrations tested
(Fig. 2); these equilibrium times were
shorter than would be predicted by the dissociation data. Association
experiments were conducted with the following concentrations of
[125I]RTI-55: 20, 50, 80, 220, and 400 pM for
all transporters; in addition, 1, 3, 6, and 10 nM were tested for hNET.
The kobs value was determined for each
experiment by nonlinear regression of the data. A single association
rate was the best fit to the data in most experiments (hDAT, 16 of 17 experiments; hSERT, 17 of 18 experiments; hNET, 39 of 42 experiments).
The k+1 value for the three
transporters, determined by linear regression of the concentration of
ligand versus the kobs value (Fig. 2),
was 0.160, 0.124, and 0.0029 nM1
min1 for HEK-hDAT, -hSERT, and -hNET,
respectively. Binding to HEK-hNET had a significantly slower
association rate than binding to HEK-hDAT or -hSERT.
Kd values calculated from the kinetic
data are 0.18, 0.13, and 6.8 nM for HEK-hDAT, -hSERT, and -hNET,
respectively.
|
|
Saturation equilibrium binding experiments were conducted by reducing
the specific activity of [125I]RTI-55 through
progressive dilution with unlabeled ligand. Figure 3 shows the saturation isotherm and
Scatchard plot for each of the transporters stably expressed in HEK
cells: the Kd and
Bmax values are given in Table
1. As the linear Scatchard plots
indicate, only a single high-affinity binding site was detected with
each transporter with ligand concentrations ranging from 30 pM to 17 nM.
|
|
Time courses for [3H]neurotransmitter uptake were conducted with each cell line to determine time points within the linear portion of the uptake time curve. Both HEK-hSERT and HEK-hNET cells exhibited uptake rates that were linear for 20 to 30 min, whereas for HEK-hDAT cells, the uptake rate began to plateau after 10 min (data not shown). Thus, for all cell lines, subsequent [3H]neurotransmitter uptake assays were conducted using a 10-min incubation.
To determine whether substrates may be depleted over long preincubation times or whether short preincubation times may give an artificially reduced affinity for slowly associating drugs, the influence of preincubation time was determined using four drugs: amphetamine (a substrate), mazindol, cocaine, and desipramine (structurally dissimilar nonsubstrate inhibitors with widely differing affinity for the hDAT). Preincubation times from 1 to 30 min were tested (Table 2). The only significant differences in IC50 values were between the 1- and 10-min preincubation time points for amphetamine for inhibition of [3H]DA uptake and between the 1- and 10-min preincubation time points for desipramine inhibition of [125I]RTI-55 binding to hDAT (p < .05, one-way ANOVA). A 10-min preincubation time was used in subsequent [125I]RTI-55 and [3H]nisoxetine binding assays and in [3H]neurotransmitter uptake assays for all drugs and all transporters.
|
To determine the rank order of potency of an array of drugs, including substrates, abused substances, antidepressants, and other therapeutic agents, at each of the biogenic amine transporters expressed in HEK 293 cells, drugs were tested for inhibition of [125I]RTI-55 binding and [3H]neurotransmitter uptake (Table 3). For hDAT, there was a good correlation between inhibitory potency at uptake and binding for all drugs; however, the correlation for nonsubstrate inhibitors was better than that for substrates (r2 = 0.633 for all drugs, r2 = 0.921 for inhibitors, r2 = 0.687 for substrates; Fig. 4A). Substrates, including DA, 5-HT, NE, methamphetamine, d-amphetamine, and (+)-fenfluramine, were uniformly more potent at inhibition of [3H]DA uptake compared with inhibition of [125I]RTI-55 binding. For hSERT, there was an excellent correlation between inhibitory potency at uptake and binding, with high correlations for both subgroups (r2 = 0.832 for all drugs, r2 = 0.938 for inhibitors, r2 = 0.936 for substrates; Fig. 4B). For hNET, the correlation between the ability of compounds to inhibit [125I]RTI-55 binding and [3H]NE uptake was less strong (r2 = 0.444 for all drugs, r2 = 0.839 for inhibitors, r2 = 0.597 for substrates; Fig. 5A). Due to the lower correlation in the pharmacological profile of inhibition of [125I]RTI-55 binding and [3H]NE uptake, drugs were tested for inhibition of [3H]nisoxetine binding to hNET membranes. There was excellent correlation between the potency of drugs at inhibiting [125I]RTI-55 and [3H]nisoxetine binding (r2 = 0.874 for all drugs, Fig. 5C). However, the use of [3H]nisoxetine rather than [125I]RTI-55 gave a similar correlation between inhibition of binding and [3H]NE uptake (r2 = 0.367 for all drugs, r2 = 0.767 for inhibitors, r2 = 0.667 for substrates; Fig. 5B). For both radioligands, the correlation coefficients increased when only drugs that are nonsubstrate inhibitors were included in the analysis. Several compounds had Hill slopes significantly less than unity for inhibition of [3H]DA or [3H]NE uptake (benztropine, DA, methamphetamine, 5-HT), which could indicate more than one affinity state or site for these drugs on the transporters.
|
|
|
The selectivity of the transporters for the stereoisomers of two
substrates was examined (Table 4). For
both HEK-hDAT and -hSERT, the potency of d-amphetamine was
greater than l-amphetamine for inhibition of
[3H]neurotransmitter uptake (p = .03 for hDAT, p = .003 for hSERT, one-tailed
t test), whereas there was no stereoselectivity for inhibition of [3H]NE uptake into HEK-hNET cells
(p = .31). d-Amphetamine had higher potency
than l-amphetamine for inhibition of
[125I]RTI-55 binding to all three transporters
(p = .04, p = .003, and
p = .01 for HEK-hDAT, -hNET, and -hSERT,
respectively). For the stereoisomers of fenfluramine, (+)-fenfluramine
was significantly more potent than (
)-fenfluramine at inhibition of
[3H]neurotransmitter uptake by all three
transporters, whereas stereoselectivity of inhibition of
[125I]RTI-55 binding was observed only in
HEK-hSERT cells (p = .002).
|
| |
Discussion |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
The interaction of cocaine with a unique binding site of a
particular transporter may contribute to euphoria. Although many clinically useful anorectic agents or antidepressants bind to neurotransmitter transporters, they lack the psychotomimetic effects of
cocaine, and some have been tested clinically as therapeutics for
cocaine abuse (Gawin et al., 1989; Preston et al., 1993). Thus, an
understanding of the mechanisms involved in the binding of drugs and
neurotransmitters to transporters, and the sequellae of
drug-transporter interaction, could indicate new directions for the
development of therapeutic agents for drug abuse.
A cocaine analog, [3H]CFT, bound to
two-affinity states in membranes of COS-7 cells expressing recombinant
rat DAT (Boja et al., 1992a) and to a one-affinity state in membranes
of COS-7 cells expressing recombinant hDAT (Eshleman et al., 1995).
RTI-55 (-CIT), a cocaine analog with high affinity for both hDAT and hSERT (Boja et al., 1992b), consistently binds to a single site in
membranes from HEK 293 cells stably expressing the hDAT, hNET, or hSERT
(Figs. 1-3; Table 1), in agreement with results from Qian et al.
(1997) involving binding to the hSERT. RTI-55 had high affinity for
hDAT (1.8 nM) and hSERT (0.98 nM), whereas the affinity for hNET (12 nM) was approximately 1 order of magnitude lower. Both dissociation and
association curves (Figs. 1 and 2) were adequately described as
reversible binding of RTI-55 to a homogeneous population of independent
binding sites. Although the Kd values determined by kinetic and saturation analyses were not identical, the
rank order of affinity of RTI-55 for the transporters was maintained
with both types of analyses.
The Kd value obtained with HEK-hDAT
cells by equilibrium binding of [125I]RTI-55
(Table 1) was identical to the lower affinity state in human striatal
preparations (Little et al., 1993; Staley et al., 1994). For HEK-hSERT,
the Kd value was similar to the
affinity of the single site in human occipital cortical membranes
detected by Little et al. (1993) and midway between the affinities
detected by Staley et al. (1994). Rothman et al. (1994) observed two
binding sites for [125I]RTI-55 in rat caudate
and a single binding site in COS cells expressing recombinant rat DAT,
consistent with the present results. These differences between
cell-expression systems and native tissue could be due to differences
in glycosylation (Patel et al., 1993) or other posttranslational
modifications such as altered steady-state phosphorylation of the
transporters or other proteins that affect the affinity for the ligand.
Seven antidepressants were tested at the three transporters. Bupropion,
desipramine, nisoxetine, nomifensine, and nortriptyline were most
potent at inhibition of [3H]NE uptake, whereas
fluoxetine and imipramine were most potent at inhibition of
[3H]5-HT uptake. Except for bupropion and
imipramine, this transporter selectivity is identical to that reported
for inhibition of [3H]neurotransmitter uptake
in rat brain membranes (Richelson and Pfenning, 1984). The transporter
selectivity of antidepressants for inhibition of uptake and
[125I]RTI-55 binding was similar (Table 3),
except bupropion and nomifensine were more potent at inhibition of
radioligand binding to HEK-hDAT than to HEK-hNET. The selectivity of
antidepressants for displacement of
[125I]RTI-55 binding was identical with that
reported for displacement of other selective radioligands (Tatsumi et
al., 1997), except for displacement by bupropion, which may indicate a
ligand-specific effect.
DA and NE had higher affinity for the hNET than for the hDAT. These
results are qualitatively similar to the 4- and 10-fold higher affinity
of DA and NE for hNET compared with hDAT, as reported by Giros et al.
(1994). Both neurotransmitters were fully efficacious at the hDAT and
hNET, emphasizing the similarity of the transport mechanism by these
two proteins.
Barker et al. (1994) investigated the differences between rat and human
SERTs expressed in HeLa cells. The Ki
values for imipramine and desipramine in the present study were similar
to values reported for hSERT (Barker et al., 1994), whereas the
Ki value for nortriptyline (Table 3)
was similar to the value reported for rat SERT. In addition, the
potency of d-amphetamine for inhibition of
[3H]5-HT uptake was more similar to the value
for rat SERT than for hSERT (Barker et al., 1994) but similar to that
reported by Ramamoorthy et al. (1993) for hSERT.
In general, the Ki values for drug
inhibition of [3H]nisoxetine binding to the
hNET, as well as the radioligand Kd
value, were 10-fold greater than results for rat cerebral cortical
membranes (Tejani-Butt et al., 1990). Possible explanations for this
consistent discrepancy may involve the difference in native versus
non-neuronal systems, leading to variations in glycosylation as
discussed, or in species differences in the affinity of rat and hNET.
We observed lower correlations between ligand binding and
neurotransmitter uptake for hNET compared with correlations for hDAT or
hSERT. The correlations between binding and uptake for hNET and hSERT
were significantly different (z = 2.143, Fisher's Z transformation; Downie and Heath, 1974), suggesting that
the RTI-55 binding site on the hSERT is more closely linked to sites of
drug interactions with substrate translocation. The movement of
neurotransmitter across the membrane by the transporter involves an
initial binding event followed by translocation of the amine across the
membrane. The lower correlation between binding and uptake at hNET,
when [125I]RTI-55 was used, may be related to
the lower rate of association of this ligand with the hNET, suggesting
that the ligand does not interact with the hNET in the same way as it
does with the hDAT or hSERT. The use of one cell type stably expressing
each of the transporters eliminates the variables introduced by
different cell types (glycosylation differences, possible metabolism of drugs, differing populations of receptors and transport proteins).
The psychostimulants d- and l-amphetamine
displayed stereoselectivity for inhibition of
[3H]neurotransmitter uptake at the hDAT and
hSERT but not at the hNET, which is in agreement with the findings of
Giros et al. (1994). However, stereoselectivity was observed at all
transporters for inhibition of binding. For the fenfluramine isomers,
stereoselectivity for inhibition of binding was observed only with
hSERT, whereas stereoselectivity for inhibition of
[3H]neurotransmitter uptake was observed in all
three cell lines. These results suggest that stereoisomers interact
differentially with binding and translocation sites in the transporter molecules.
The binding site of cocaine on the hDAT may be sufficiently different
from the recognition site for DA that a drug will be able to inhibit
the binding of cocaine without blocking DA uptake (Rothman et al.,
1993). This hypothesis is supported by differential effects on DA
uptake and cocaine ligand binding after single amino acid substitutions
on the DAT (Kitayama et al., 1992), by examination of DAT/NET chimeras
(Giros et al., 1994; Buck and Amara, 1995), and by some animal
self-administration studies (Tella et al., 1996, but see Roberts, 1993,
and Wojnicki and Glowa, 1996). One method of screening for a
pharmacological cocaine antagonist would be to compare the potencies of
compounds for inhibition of DA uptake and cocaine analog binding. A
compound that has greater potency at inhibition of binding than uptake
may be a potential "DA-sparing" cocaine antagonist. In addition,
determination of the potencies of compounds at the SERT and NET would
establish the selectivity of drugs.
Rothman et al. (1993) observed differences in the ratio of uptake and
binding potency for one of three drugs when uptake and binding assays
were conducted under identical conditions versus assays using different
buffers, incubation temperatures and times, and membrane preparations.
In the current report, although identical preincubation times and
buffers were used, the incubation times for these inherently different
experiments (equilibrium binding versus uptake during the linear
portion of the time course) were different, as were the tissue
preparations. A total particulate membrane preparation was used for
binding due to the possible confounds of intact cells, including
internalization of transporters or sequestration of drug.
Desipramine, fluoxetine, and nortriptyline were more potent at
inhibition of binding than uptake at the hDAT, by factors of 6, 3, and
4, respectively (Table 3). Interestingly, Slusher et al. (1997), who
tested drugs under identical conditions for
[3H]DA uptake and
[3H]CFT binding, also identified desipramine as
having much greater potency at inhibition of binding. However, the
higher potency (3 orders of magnitude) at the hNET (desipramine and
nortriptyline) and hSERT (fluoxetine, Table 3) reveals the lack of
selectivity for the hDAT by these antidepressants; therefore, they are
unlikely candidates for therapeutic cocaine antagonists. In addition,
five drugs were more potent at inhibition of binding to hSERT than at
inhibition of [3H]5-HT uptake. Interestingly,
all except GBR-12935 are therapeutic agents, and close analogs of
GBR-12935 have potential as therapeutic agents for cocaine abuse (Glowa
et al., 1996; Tella et al., 1996). No drug was more potent at
inhibition of [125I]RTI-55 binding to hNET than
at inhibition of [3H]NE uptake. Structural
differences among the transporters may account for the varying potency
ratios between the uptake and binding of a drug at the three
transporters. Critical residues for the recognition of drugs may differ
among the transporters, and the detection of a drug that is selective
for a single transporter, with the ability to inhibit the binding of an
abused substance, such as cocaine, while sparing neurotransmitter
uptake may be accomplished using the assays reported here.
| |
Acknowledgments |
|---|
We thank Robert A. Johnson, Carey Teemer, and Alan Goodhue for technical assistance.
| |
Footnotes |
|---|
Accepted for publication December 18, 1998.
Received for publication September 29, 1998.
1 This work was supported by National Institutes of Health Contracts NO1-DA-3-8303 and NO1-DA-7-8071, Department of Veterans Affairs Merit Review and Career Scientist Programs, and a Young Investigator Award from NARSAD.
Send reprint requests to: Dr. Amy Eshleman, Research Service RD-22, Veterans Affairs Medical Center, 3710 S.W. U.S. Veterans Hospital Road, Portland, OR 97201. E-mail eshleman{at}ohsu.edu
| |
Abbreviations |
|---|
DA, dopamine;
hDAT, human dopamine transporter;
5-HT, 5-hydroxytryptamine (serotonin);
hSERT, human serotonin
transporter;
NE, norepinephrine;
hNET, human norepinephrine
transporter;
HEK, human embryonic kidney 293 cells;
HEK-hDAT, HEK-hSERT, or HEK-hNET cells, human embryonic kidney 293 cells
transfected with hDAT, hSERT, or hNET cDNA, respectively;
CFT, 2
carbomethoxy-3-(4-fluorophenyl)tropane;
GBR-12935, 1-[2-diphenylmethoxy]ethyl-4-(3-phenylpropyl)-piperazine.
| |
References |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
This article has been cited by other articles:
|
|
 |
|
  J. X. Kelly, M. J. Smilkstein, R. A. Cooper, K. D. Lane, R. A. Johnson, A. Janowsky, R. A. Dodean, D. J. Hinrichs, R. Winter, and M. Riscoe Design, Synthesis, and Evaluation of 10-N-Substituted Acridones as Novel Chemosensitizers in Plasmodium falciparum Antimicrob. Agents Chemother., November 1, 2007; 51(11): 4133 - 4140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhou, J. Zhen, N. K. Karpowich, R. M. Goetz, C. J. Law, M. E. A. Reith, and D.-N. Wang LeuT-Desipramine Structure Reveals How Antidepressants Block Neurotransmitter Reuptake Science, September 7, 2007; 317(5843): 1390 - 1393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Basile, A. Janowsky, K. Golembiowska, M. Kowalska, E. Tam, M. Benveniste, P. Popik, A. Nikiforuk, M. Krawczyk, G. Nowak, et al. Characterization of the Antinociceptive Actions of Bicifadine in Models of Acute, Persistent, and Chronic Pain J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1208 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fowler, N. Seifert, V. Acker, T. Woehrle, C. Kilpert, and A. de Saizieu A Nonradioactive High-Throughput/High-Content Assay for Measurement of the Human Serotonin Reuptake Transporter Function In Vitro J Biomol Screen, December 1, 2006; 11(8): 1027 - 1034. [Abstract] [PDF]
|
|
|
|
|
|
G. M. Miller, C. D. Verrico, A. Jassen, M. Konar, H. Yang, H. Panas, M. Bahn, R. Johnson, and B. K. Madras Primate Trace Amine Receptor 1 Modulation by the Dopamine Transporter J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 983 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Kreek, G. Bart, C. Lilly, K. S. Laforge, and D. A. Nielsen Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments Pharmacol. Rev., March 1, 2005; 57(1): 1 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Beer, J. Stark, P. Krieter, P. Czobor, G. Beer, A. Lippa, and P. Skolnick DOV 216,303, a "Triple" Reuptake Inhibitor: Safety, Tolerability, and Pharmacokinetic Profile J. Clin. Pharmacol., December 1, 2004; 44(12): 1360 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Wilhelm, R. A. Johnson, P. G. Lysko, A. J. Eshleman, and A. Janowsky Effects of Methamphetamine and Lobeline on Vesicular Monoamine and Dopamine Transporter-Mediated Dopamine Release in a Cotransfected Model System J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1142 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Miller, P. A. Crooks, G. Zheng, V. P. Grinevich, S. D. Norrholm, and L. P. Dwoskin Lobeline Analogs with Enhanced Affinity and Selectivity for Plasmalemma and Vesicular Monoamine Transporters J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1035 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Chen, J. Rickey, J. L. Berfield, and M. E. A. Reith Aspartate 345 of the Dopamine Transporter Is Critical for Conformational Changes in Substrate Translocation and Cocaine Binding J. Biol. Chem., February 13, 2004; 279(7): 5508 - 5519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Roman, S. N. Saldana, D. E. Nichols, F. I. Carroll, and E. L. Barker Distinct Molecular Recognition of Psychostimulants by Human and Drosophila Serotonin Transporters J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 679 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Sharpe, E. Palant, C. I. Schroeder, D. M. Kaye, D. J. Adams, P. F. Alewood, and R. J. Lewis Inhibition of the Norepinephrine Transporter by the Venom Peptide {chi}-MrIA: SITE OF ACTION, Na+ DEPENDENCE, AND STRUCTURE-ACTIVITY RELATIONSHIP J. Biol. Chem., October 10, 2003; 278(41): 40317 - 40323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Wang, M. S. Sonders, O. T. Ukairo, H. Scott, M. K. Kloetzel, and C. K. Surratt Dissociation of High-Affinity Cocaine Analog Binding and Dopamine Uptake Inhibition at the Dopamine Transporter Mol. Pharmacol., August 1, 2003; 64(2): 430 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Martel, R. Monteiro, and C. Lemos Uptake of Serotonin at the Apical and Basolateral Membranes of Human Intestinal Epithelial (Caco-2) Cells Occurs through the Neuronal Serotonin Transporter (SERT) J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 355 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Hahn, D. Robertson, and R. D. Blakely A Mutation in the Human Norepinephrine Transporter Gene (SLC6A2) Associated with Orthostatic Intolerance Disrupts Surface Expression of Mutant and Wild-Type Transporters J. Neurosci., June 1, 2003; 23(11): 4470 - 4478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Moron, A. Brockington, R. A. Wise, B. A. Rocha, and B. T. Hope Dopamine Uptake through the Norepinephrine Transporter in Brain Regions with Low Levels of the Dopamine Transporter: Evidence from Knock-Out Mouse |
